

Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 3, Number 5


May 2004

Articles

- Multiparametric evaluation of apoptosis: Effects of standard cytotoxic agents and the cyanoguanidine CHS 828** 521
Henrik Lövborg, Peter Nygren, and Rolf Larsson
- The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling** 527
G. Sakuntala Warshamana-Greene, Julie Litz, Elisabeth Buchdunger, Francesco Hofmann, Carlos García-Echeverría, and Geoffrey W. Krystal
- Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells** 537
Elvira Crescenzi, Linda Varriale, Mariangela Iovino, Angela Chiaviello, Bianca Maria Veneziani, and Giuseppe Palumbo
- Antisense oligonucleotides directed at the *bcl-xl* gene product augment chemotherapy response in mesothelioma** 545
Mustafa K. Ozvaran, Xiaobo X. Cao, Steven D. Miller, Brett A. Monia, Waun Ki Hong, and W. Roy Smythe
- Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity** 551
Edward G. Mimnaugh, Wanping Xu, Michele Vos, Xitong Yuan, Jennifer S. Isaacs, Kheem S. Bisht, David Gius, and Len Neckers
- Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G₂-M-phase cell cycle arrest in PC-3 human prostate cancer cells** 567
Dong Xiao, Candace S. Johnson, Donald L. Trump, and Shivendra V. Singh
- DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, hedamycin, a pluramycin antitumor antibiotic** 577
Lan Chun Tu, Thomas Melendy, and Terry A. Beerman
- The novel estrogen 17 α -20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17 β -diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations *in vitro*** 587
James A. Mobley, James O. L'Esperance, Mengchu Wu, Carolyn J. Friel, Robert H. Hanson, and Shuk-Mei Ho

contents continued

Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen	597
Shawn E. Lupold and Ronald Rodriguez	
Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription	605
Sung Dae Cho, Cheng Jiang, Barbara Malewicz, Yan Dong, Charles Y. F. Young, Kyung-Sun Kang, Yong-Soon Lee, Clement Ip, and Junxuan Lü	
Different DNA lesions trigger distinct cell death responses in HCT116 colon carcinoma cells	613
Shaochun Bai and David W. Goodrich	
Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated–dependent and –independent mechanisms	621
Wai Yi Siu, Anita Lau, Talha Arooz, Jeremy P. H. Chow, Horace T. B. Ho, and Randy Y. C. Poon	
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy	633
Valerie Gouazé, Jing Y. Yu, Richard J. Bleicher, Tie-Yan Han, Yong-Yu Liu, Hongtao Wang, Michael M. Gottesman, Arie Bitterman, Armando E. Giuliano, and Myles C. Cabot	
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer	641
Phillip J. Gray, Jr., David J. Bearss, Haiyong Han, Raymond Nagle, Ming-Sound Tsao, Nicholas Dean, and Daniel D. Von Hoff	
Minireview	
Hypoxia inducible factor-1α as a cancer drug target	647
Garth Powis and Lynn Kirkpatrick	
Instructions for Authors	<i>i</i>



On the Cover

The novel estrogen analog 17 α -20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10), 20-tetraene-3,17 β -diol (APVE₂) is shown minimized within the ligand binding pocket of both estrogen-receptor subtypes alpha (1ERE, *blue*) and beta (1QKM, *orange*). This molecule was chosen from a small library of 17 α -modified-E₂ analogues originally designed for ER- β specificity. In a competition binding assay, APVE₂ was shown to exhibit moderate yet selective binding to ER β . For details, see Mobley *et al.* in this issue.